Tristan X. McCallister
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tristan X. McCallister has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Christian Saporito-Magriña
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Ciencias Químicas, Cátedra de Química General e Inorgánica, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Bioquímica y Medicina Molecular Prof. Alberto Boveris (IBIMOL, UBA-CONICET), Buenos Aires, Argentina
1 shared publication Colin K. W. Lim
Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA
1 shared publication- Garrett D. McPheron
Institute for Stem Cell and Regenerative Medicine, Seattle, USA
1 shared publication - Jackson E. Powell
Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA
1 shared publication - M. Alejandra Zeballos C.
Department of Bioengineering, The Grainger College of Engineering, University of Illinois Urbana-Champaign, Urbana, USA
1 shared publication Ramya Krishnan
Department of Bioengineering, University of Illinois, Urbana, IL 61801, USA
1 shared publication
Latest Publications
- Open Access
- 21 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (3) , eabk2485
Targeted gene silencing in the nervous system with CRISPR-Cas13
Cas13 nucleases are a class of programmable RNA-targeting CRISPR effector proteins that are capable of silencing target gene expression in mammalian cells. Here, we demonstrate that RfxCas13d, a Cas13 ortholog with favorable characteristics to other family members, can be delivered to the mouse spinal cord and brain to silence neurodegeneration-associated genes. Intrathecally delivering an adeno-associated virus vector encoding an RfxCas13d variant programmed to target superoxide dismutase 1 (SOD1), a protein whose mutation can cause amyotrophic lateral sclerosis, reduced SOD1 mRNA and protein in the spinal cord by >50% and improved outcomes in a mouse model of the disorder. We further show that intrastriatally delivering an RfxCas13d variant programmed to target huntingtin (HTT), a protein whose mutation is causative for Huntington’s disease, led to a ~50% reduction in HTT protein in the mouse brain. Our results establish RfxCas13d as a versatile platform for knocking down gene expression in the nervous system.
- 21 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (3) , eabk2485
Open AccessTargeted gene silencing in the nervous system with CRISPR-Cas13
Cas13 nucleases are a class of programmable RNA-targeting CRISPR effector proteins that are capable of silencing target gene expression in mammalian cells. Here, we demonstrate that RfxCas13d, a Cas13 ortholog with favorable characteristics to other family members, can be delivered to the mouse spinal cord and brain to silence neurodegeneration-associated genes. Intrathecally delivering an adeno-associated virus vector encoding an RfxCas13d variant programmed to target superoxide dismutase 1 (SOD1), a protein whose mutation can cause amyotrophic lateral sclerosis, reduced SOD1 mRNA and protein in the spinal cord by >50% and improved outcomes in a mouse model of the disorder. We further show that intrastriatally delivering an RfxCas13d variant programmed to target huntingtin (HTT), a protein whose mutation is causative for Huntington’s disease, led to a ~50% reduction in HTT protein in the mouse brain. Our results establish RfxCas13d as a versatile platform for knocking down gene expression in the nervous system.